Medical School · Year 1 · Foundations · includes a quiz and discussion video

Lecture 4: Enzyme Kinetics and Regulation

Unit 1.1: Foundations of Medicine & Medical Sciences

Learning Objectives

By the end of this lecture, students will be able to:

1. Apply Michaelis-Menten kinetics to describe enzyme behavior and calculate Km and Vmax from experimental data
2. Distinguish between competitive, non-competitive, uncompetitive, and mixed inhibition and predict their effects on kinetic parameters
3. Explain allosteric regulation and its role in metabolic control
4. Describe mechanisms of covalent enzyme modification including phosphorylation
5. Relate enzyme kinetics to drug mechanism and therapeutic applications
6. Interpret Lineweaver-Burk plots to determine inhibition type

Lecture Content

I. Introduction to Enzymes

Enzymes are the molecular machines that make life possible, accelerating chemical reactions by factors of 10⁶ to 10¹² compared to uncatalyzed rates. Without enzymes, metabolic reactions essential for life would occur far too slowly to sustain biological processes. Enzymes achieve this remarkable rate enhancement by lowering the activation energy (Ea) required to reach the transition state, while leaving the overall free energy change (ΔG) of the reaction unchanged. They are highly specific, typically catalyzing only one reaction or a small set of closely related reactions, and they emerge from reactions unchanged, ready to catalyze additional cycles.

Enzyme Classification

The International Union of Biochemistry and Molecular Biology classifies enzymes into six major classes based on the type of reaction they catalyze, with each enzyme receiving a unique EC (Enzyme Commission) number. Oxidoreductases catalyze oxidation-reduction reactions, transferring electrons between molecules; lactate dehydrogenase exemplifies this class by converting lactate to pyruvate while reducing NAD⁺ to NADH. Transferases move functional groups from one molecule to another—hexokinase transfers a phosphate group from ATP to glucose. Hydrolases use water to break bonds, as seen with trypsin cleaving peptide bonds in proteins. Lyases catalyze the non-hydrolytic addition or removal of groups, often creating or destroying double bonds; aldolase cleaves fructose-1,6-bisphosphate during glycolysis. Isomerases catalyze intramolecular rearrangements, converting molecules between isomeric forms. Finally, ligases use ATP energy to join molecules together through new covalent bonds, as DNA ligase does when sealing breaks in the DNA backbone.

The Active Site

All enzymatic catalysis occurs at the active site, a specialized pocket or cleft within the enzyme's three-dimensional structure. This region binds the substrate through non-covalent interactions—hydrogen bonds, electrostatic attractions, hydrophobic contacts, and van der Waals forces—positioning it precisely for the chemical transformation. The active site also contains catalytic residues that directly participate in bond breaking and forming.

Two models describe how substrates bind to enzymes. The lock-and-key model, proposed by Emil Fischer, envisions the active site as a rigid template perfectly complementary to the substrate shape. The induced fit model, developed by Daniel Koshland, better reflects experimental observations: the enzyme undergoes conformational changes upon substrate binding, molding itself around the substrate to achieve optimal complementarity. This conformational change often brings catalytic groups into proper alignment and excludes water from the active site.

<image>Panel A: Lock-and-key model with rigid enzyme (gray) containing precisely shaped purple pocket and blue substrate fitting exactly. Panel B: Lock-and-key bound complex showing unchanged enzyme shape after substrate binding. Panel C: Induced fit model with enzyme showing flexible active site (dashed lines) before substrate binding. Panel D: Induced fit conformational change with arrows showing enzyme wrapping around substrate and catalytic residues moving to optimal positions.</image>

II. Michaelis-Menten Kinetics

The quantitative study of enzyme kinetics began with the work of Leonor Michaelis and Maud Menten, who developed a mathematical framework that remains fundamental to understanding enzyme behavior. Their model describes a simple enzymatic reaction in which the enzyme (E) binds reversibly to substrate (S) to form an enzyme-substrate complex (ES), which then converts to product (P) and regenerates the free enzyme.

The Basic Model and Assumptions

The reaction sequence can be written as: E + S ⇌ ES → E + P, where k₁ represents the rate of ES formation from E and S, k₋₁ represents the rate of ES dissociation back to E and S, and k₂ (also called kcat) represents the catalytic rate at which ES converts to E + P. The Michaelis-Menten analysis assumes that substrate concentration vastly exceeds enzyme concentration ([S] >> [E]), so substrate consumption doesn't significantly affect [S] during initial rate measurements. It also assumes a steady state, where the rate of ES formation equals the rate of ES breakdown, keeping [ES] constant during the measurement.

The Michaelis-Menten Equation

These assumptions lead to the Michaelis-Menten equation: v = Vmax[S] / (Km + [S]). This equation describes a rectangular hyperbola relating reaction velocity (v) to substrate concentration ([S]). At low substrate concentrations where [S] << Km, velocity increases nearly linearly with [S]. At high concentrations where [S] >> Km, velocity approaches the maximum velocity Vmax asymptotically, as the enzyme becomes saturated with substrate.

Kinetic Parameters

The Michaelis constant (Km) equals the substrate concentration at which the reaction velocity reaches half of Vmax. Importantly, Km provides an inverse measure of the enzyme's affinity for substrate: a low Km indicates high affinity (the enzyme achieves half-maximal velocity at low substrate concentrations), while a high Km indicates lower affinity. Km values typically fall in the micromolar to millimolar range and have units of concentration.

The maximum velocity (Vmax) represents the reaction rate when every enzyme molecule is occupied by substrate. Vmax depends directly on the total enzyme concentration: Vmax = kcat × [E]total. This relationship explains why Vmax increases when more enzyme is present.

The turnover number (kcat) expresses the intrinsic catalytic power of an enzyme as the number of substrate molecules converted to product per enzyme molecule per second when the enzyme is fully saturated. Turnover numbers vary enormously across enzymes, from approximately 1 s⁻¹ for slow enzymes to over 10⁷ s⁻¹ for carbonic anhydrase.

Catalytic efficiency, expressed as the ratio kcat/Km, provides an overall measure of how effectively an enzyme captures and converts substrate. This second-order rate constant approaches an upper limit of 10⁸ to 10⁹ M⁻¹s⁻¹, the rate at which substrate can diffuse to the enzyme active site. Enzymes approaching this limit are said to have achieved "catalytic perfection."

<image>Panel A: Michaelis-Menten curve showing hyperbolic relationship between velocity (y-axis) and substrate concentration (x-axis) with Vmax asymptote. Panel B: Linear region at low [S] labeled first-order kinetics with v proportional to [S]. Panel C: Km marked at v = Vmax/2 with vertical dashed line to x-axis showing transition zone. Panel D: Plateau region at high [S] labeled zero-order kinetics with inset boxes showing mathematical relationships.</image>

III. Lineweaver-Burk Plot

While the Michaelis-Menten equation accurately describes enzyme kinetics, the hyperbolic curve makes it difficult to determine Km and Vmax precisely from experimental data. Hans Lineweaver and Dean Burk addressed this problem by taking the reciprocal of both sides of the Michaelis-Menten equation, producing a linear relationship: 1/v = (Km/Vmax)(1/[S]) + 1/Vmax.

This double reciprocal plot yields a straight line when 1/v is plotted against 1/[S]. The y-intercept equals 1/Vmax, allowing direct determination of the maximum velocity. The x-intercept equals -1/Km, providing the Michaelis constant. The slope equals Km/Vmax. This linearization makes it straightforward to extract kinetic parameters from experimental data using simple linear regression.

The Lineweaver-Burk plot proves particularly valuable for analyzing enzyme inhibition, as different inhibition types produce characteristic and distinguishable patterns when comparing lines obtained in the presence and absence of inhibitor. However, the transformation does have limitations: it disproportionately weights data points obtained at low substrate concentrations (which have large 1/[S] values), and these points are often the least accurate experimentally due to slow reaction velocities.

<image>Panel A: Lineweaver-Burk plot with 1/v on y-axis and 1/[S] on x-axis showing straight line through five data points. Panel B: Y-axis intersection labeled 1/Vmax with bracket and arrow in first quadrant. Panel C: X-axis intersection at -1/Km in negative region (second quadrant) with slope labeled Km/Vmax. Panel D: Inset showing transformation from hyperbolic Michaelis-Menten curve to linear double reciprocal representation.</image>

IV. Enzyme Inhibition

Enzyme inhibitors reduce catalytic activity and are critically important both for metabolic regulation and for pharmacology. Understanding inhibition mechanisms allows prediction of drug effects and guides therapeutic development.

Reversible Inhibition

Reversible inhibitors bind to enzymes through non-covalent interactions and can dissociate, restoring enzyme activity. Four major types of reversible inhibition are distinguished by where the inhibitor binds and how it affects kinetic parameters.

Competitive inhibition occurs when the inhibitor binds to the enzyme's active site, directly competing with substrate for the same binding location. Because inhibitor and substrate cannot bind simultaneously, high substrate concentrations can outcompete the inhibitor and restore activity. Competitive inhibitors increase the apparent Km (more substrate is required to achieve half-maximal velocity) but leave Vmax unchanged (the maximum velocity can still be achieved if enough substrate is present). On a Lineweaver-Burk plot, competitive inhibition produces lines that intersect on the y-axis: the y-intercept (1/Vmax) remains constant while the x-intercept (-1/Km) shifts. Statins provide an important clinical example—they compete with HMG-CoA for binding to HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis.

Non-competitive inhibition occurs when the inhibitor binds to a site separate from the active site and does so equally well whether or not substrate is bound. This binding reduces the enzyme's catalytic capability without affecting substrate binding. Km remains unchanged, but Vmax decreases because a fraction of enzyme molecules are rendered inactive regardless of substrate concentration. On a Lineweaver-Burk plot, lines intersect on the x-axis: the x-intercept (-1/Km) is unchanged while the y-intercept (1/Vmax) increases. Heavy metals that bind to cysteine residues often cause non-competitive inhibition.

Uncompetitive inhibition occurs when the inhibitor binds only to the enzyme-substrate complex, not to free enzyme. This unusual mechanism requires substrate binding before inhibitor can bind. Both Km and Vmax decrease, producing parallel lines on a Lineweaver-Burk plot (same slope but different intercepts). Uncompetitive inhibition is rare for single-substrate reactions but occurs more commonly in multi-substrate enzyme reactions.

Mixed inhibition represents the most general case, where the inhibitor can bind to both free enzyme and the enzyme-substrate complex but with different affinities. The effects on kinetic parameters depend on the relative binding affinities, but generally Vmax decreases while Km may increase or decrease. Lineweaver-Burk lines intersect at a point that is neither on the x-axis nor the y-axis, typically in the second or third quadrant.

<image>Panel A: Competitive inhibition Lineweaver-Burk plot with lines intersecting on y-axis, steeper inhibited slope, and diagram of inhibitor competing for active site. Panel B: Non-competitive inhibition with lines intersecting on x-axis, same x-intercept but higher y-intercept, and allosteric binding diagram. Panel C: Uncompetitive inhibition showing parallel lines with inhibited line shifted, and diagram of inhibitor binding only to ES complex. Panel D: Mixed inhibition with lines intersecting in second quadrant and diagram showing inhibitor binding to both E and ES with Km/Vmax effects table.</image>

Irreversible Inhibition

Irreversible inhibitors form covalent bonds with enzyme residues, permanently inactivating the enzyme. Activity cannot be restored by dilution or dialysis; new enzyme synthesis is required to restore function. Several clinically important drugs act as irreversible inhibitors.

Aspirin irreversibly inhibits cyclooxygenase (COX) by acetylating a serine residue in the active site, blocking prostaglandin and thromboxane synthesis. This explains aspirin's anti-inflammatory effects and its antiplatelet action—platelets lack nuclei and cannot synthesize new COX, so inhibition persists for the platelet's lifetime. Penicillin and related β-lactam antibiotics irreversibly acylate bacterial transpeptidase enzymes required for cell wall synthesis. Organophosphate nerve agents and pesticides irreversibly phosphorylate the active site serine of acetylcholinesterase, preventing acetylcholine breakdown and causing persistent cholinergic stimulation.

V. Allosteric Regulation

While Michaelis-Menten kinetics adequately describes many enzymes, some key metabolic enzymes display more complex behavior that allows exquisite regulatory control. These allosteric enzymes contain regulatory sites distinct from their active sites, and binding of effector molecules at these regulatory sites modulates catalytic activity.

Characteristics of Allosteric Enzymes

Allosteric enzymes typically consist of multiple subunits and display sigmoidal rather than hyperbolic kinetics when velocity is plotted against substrate concentration. This sigmoidal relationship provides switch-like behavior: the enzyme is relatively inactive at low substrate concentrations but activity increases sharply once a threshold is reached. This allows sensitive responses to changes in metabolic conditions.

Models of Allosteric Behavior

The concerted model (also called the MWC model for Monod, Wyman, and Changeux) proposes that allosteric enzymes exist in equilibrium between two conformational states: a low-activity T (tense) state and a high-activity R (relaxed) state. All subunits change conformation simultaneously and in concert. Substrates and activators preferentially bind to and stabilize the R state, shifting the equilibrium toward activity. Inhibitors stabilize the T state, shifting equilibrium away from activity.

The sequential model (or KNF model for Koshland, Nemethy, and Filmer) proposes that subunits change conformation individually, and ligand binding to one subunit induces conformational changes that affect neighboring subunits without requiring all subunits to adopt the same state. This model can explain negative cooperativity, where binding of substrate to one site decreases affinity at other sites.

<image>Panel A: MWC concerted model showing four-subunit enzyme in T state (squares, low affinity) equilibrium with R state (circles, high affinity). Panel B: MWC model with substrate (blue triangles) binding preferentially to R state, activator (green) stabilizing R, inhibitor (red) stabilizing T. Panel C: KNF sequential model showing progressive substrate binding changing individual subunit conformations with adjacent subunits in intermediate shapes. Panel D: Comparison box highlighting MWC all-or-none transitions versus KNF gradual conformational changes.</image>

Allosteric Effectors and Cooperativity

Positive allosteric effectors (activators) increase enzyme activity by shifting the conformational equilibrium toward the R state. They may lower the apparent Km for substrate or increase Vmax. AMP serves as a positive effector of phosphofructokinase-1 (PFK-1), the key regulatory enzyme of glycolysis, signaling low energy charge and stimulating glucose oxidation.

Negative allosteric effectors (inhibitors) decrease activity by stabilizing the T state, increasing Km or decreasing Vmax. ATP inhibits PFK-1, signaling adequate energy and slowing glycolysis when cellular energy is abundant.

Cooperativity refers to the phenomenon where binding of substrate to one subunit affects substrate binding to other subunits. Positive cooperativity means that binding of the first substrate molecule increases affinity for subsequent substrates—this produces sigmoidal kinetics. Hemoglobin's oxygen binding exemplifies positive cooperativity: binding of the first oxygen facilitates binding of subsequent oxygens. The Hill coefficient (n) quantifies cooperativity: n = 1 indicates no cooperativity (Michaelis-Menten behavior), n > 1 indicates positive cooperativity, and n < 1 indicates negative cooperativity.

VI. Covalent Modification

Cells regulate enzyme activity not only through reversible binding of effectors but also through covalent chemical modifications. These modifications provide rapid, reversible control mechanisms that operate on timescales of seconds to minutes.

Phosphorylation

Phosphorylation represents the most prevalent regulatory modification in eukaryotic cells, with an estimated one-third of all proteins undergoing phosphorylation. Protein kinases catalyze the transfer of the γ-phosphate from ATP to hydroxyl-containing amino acid side chains—serine, threonine, or tyrosine. Protein phosphatases reverse this modification by catalyzing hydrolytic removal of phosphate groups.

The addition of a phosphate group introduces a bulky, negatively charged moiety that can dramatically alter protein conformation and activity. Depending on the specific enzyme and the location of the modification, phosphorylation can either activate or inhibit catalytic function. This system enables rapid switching between active and inactive states without new protein synthesis or degradation.

The reciprocal regulation of glycogen metabolism beautifully illustrates phosphorylation-based control. Glycogen synthase, which synthesizes glycogen, is active in its dephosphorylated form and inactive when phosphorylated. Glycogen phosphorylase, which breaks down glycogen, shows the opposite pattern: it is inactive when dephosphorylated and active when phosphorylated. Thus, a single kinase activation event simultaneously inhibits glycogen synthesis while activating glycogen breakdown, providing coordinated metabolic control.

<image>Panel A: Protein kinase (purple) transferring phosphate group (orange P circle) from ATP to target enzyme converting Form A (blue) to Form B (phosphorylated). Panel B: Protein phosphatase (green) removing phosphate with H2O releasing Pi to convert enzyme back to Form A in complete cycle. Panel C: Examples showing glycogen synthase (Form A active, Form B inactive) and glycogen phosphorylase (Form A inactive, Form B active). Panel D: Conformational change illustration showing phosphate negative charges interacting with positively charged residues.</image>

Other Covalent Modifications

Beyond phosphorylation, cells employ numerous other covalent modifications for regulation. Acetylation, the addition of acetyl groups from acetyl-CoA, regulates gene expression through modification of histone proteins and affects the activity of many metabolic enzymes. Methylation of DNA and histones plays crucial roles in epigenetic regulation. Ubiquitination tags proteins for degradation by the proteasome, controlling protein levels and removing damaged or misfolded proteins. Glycosylation adds carbohydrate chains to proteins, affecting folding, stability, and recognition particularly for secreted and membrane proteins.

VII. Zymogens (Proenzymes)

Some enzymes are synthesized as inactive precursors called zymogens or proenzymes, requiring proteolytic cleavage to become catalytically active. This mechanism provides an irreversible on switch for enzyme activation, appropriate for situations where activity should be triggered only at specific times and places.

Digestive Enzyme Zymogens

The digestive system provides the classic examples of zymogen biology. Proteolytic enzymes that would damage the tissues producing them are synthesized as inactive zymogens and activated only after secretion into the digestive tract. Pepsinogen, produced by gastric chief cells, contains a peptide that blocks its active site. In the acidic environment of the stomach, this peptide is cleaved off, generating active pepsin which then autocatalytically activates more pepsinogen.

The pancreas secretes trypsinogen, chymotrypsinogen, proelastase, and procarboxypeptidases into the small intestine. Enterokinase, an enzyme anchored to the intestinal epithelium, cleaves trypsinogen to produce active trypsin. Trypsin then activates the other zymogens in an amplifying cascade—each molecule of trypsin can activate many molecules of the other proenzymes.

Blood Clotting Cascade

Blood coagulation employs an elaborate cascade of zymogens to ensure that clotting occurs rapidly when needed but remains dormant in circulating blood. Each activated clotting factor activates the next zymogen in the cascade, with each step providing amplification. The cascade culminates in the conversion of prothrombin to thrombin, which cleaves fibrinogen to fibrin, forming the structural meshwork of the clot.

Clinical Significance

Premature or inappropriate zymogen activation causes serious disease. Acute pancreatitis occurs when digestive enzyme zymogens become activated within the pancreas, causing autodigestion of pancreatic tissue and severe inflammation. Disseminated intravascular coagulation (DIC) results from systemic activation of the clotting cascade, consuming clotting factors and causing both widespread microvascular thrombosis and paradoxical bleeding.

<image>Panel A: Enterokinase anchored to intestinal epithelial cells cleaving trypsinogen (gray) to active trypsin (red with scissors). Panel B: Trypsin activating four zymogens: chymotrypsinogen, proelastase, procarboxypeptidase A and B with cleaved peptide fragments. Panel C: Inset showing structural change with blocking peptide removal exposing active site. Panel D: Warning box indicating premature activation danger causing acute pancreatitis with red cross symbol.</image>

VIII. Isoenzymes (Isozymes)

Isoenzymes are different molecular forms of an enzyme that catalyze the same reaction but differ in amino acid sequence, often showing tissue-specific expression patterns. These variations reflect gene duplications during evolution, with subsequent divergence allowing optimization of enzyme properties for different cellular environments.

Lactate Dehydrogenase Isoenzymes

Lactate dehydrogenase (LDH) provides a well-studied example. LDH catalyzes the interconversion of lactate and pyruvate, functioning as a tetramer composed of H (heart) and M (muscle) subunits. The five possible tetrameric combinations—H₄ (LDH1), H₃M (LDH2), H₂M₂ (LDH3), HM₃ (LDH4), and M₄ (LDH5)—have different kinetic properties suited to their tissue locations. LDH1 predominates in heart and red blood cells and favors lactate oxidation to pyruvate; LDH5 predominates in liver and skeletal muscle and favors pyruvate reduction to lactate.

Creatine Kinase Isoenzymes

Creatine kinase (CK) catalyzes the reversible phosphorylation of creatine, maintaining ATP levels in tissues with high, fluctuating energy demands. CK exists as dimers of M and B subunits. CK-MM predominates in skeletal muscle, CK-MB is enriched in cardiac muscle, and CK-BB occurs mainly in brain and smooth muscle.

Diagnostic Applications

Isoenzyme patterns provide valuable diagnostic information because damage to specific tissues releases their characteristic isoenzyme profiles into the blood. Although troponins have largely replaced CK-MB for diagnosing myocardial infarction, the principle of tissue-specific isoenzyme release remains diagnostically useful. LDH isoenzyme patterns help identify hemolysis (LDH1 and LDH2 elevation from red blood cell destruction) and liver disease (LDH5 elevation).

<image>Panel A: Five LDH isoenzymes as tetrameric combinations of H (heart, blue) and M (muscle, red) subunits from LDH1 to LDH5. Panel B: Electrophoresis gel with LDH1 fastest migrating near anode and LDH5 slowest near cathode. Panel C: Three lane comparisons showing normal serum, myocardial infarction with flipped LDH1/LDH2 ratio, and liver disease with elevated LDH5. Panel D: Table summarizing tissue sources: LDH1-heart/RBCs, LDH2-RBCs/heart, LDH3-lungs/platelets, LDH4-kidney/placenta, LDH5-liver/skeletal muscle.</image>

IX. Pharmacological Applications

Understanding enzyme kinetics provides the foundation for rational drug design, as many successful therapeutic agents function as enzyme inhibitors.

Enzymes as Drug Targets

Statins exemplify successful enzyme-targeted therapy. These competitive inhibitors of HMG-CoA reductase block the rate-limiting step in cholesterol biosynthesis, effectively lowering serum cholesterol and reducing cardiovascular disease risk. Their design was informed by understanding that competitive inhibitors with structures resembling the transition state intermediate have highest affinity.

ACE (angiotensin-converting enzyme) inhibitors block the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, lowering blood pressure and providing cardiovascular and renal protection. Methotrexate competitively inhibits dihydrofolate reductase, blocking folate metabolism and DNA synthesis, making it effective against cancer and autoimmune diseases. Allopurinol inhibits xanthine oxidase to reduce uric acid production in gout. Aspirin's irreversible inhibition of cyclooxygenase provides anti-inflammatory, analgesic, and antiplatelet effects.

Enzyme Replacement Therapy

When genetic mutations result in deficient enzyme activity, enzyme replacement therapy can provide the missing function. Gaucher disease, caused by glucocerebrosidase deficiency leading to accumulation of glucocerebroside in macrophages, is treated with infusions of recombinant enzyme (imiglucerase). Pompe disease, resulting from acid α-glucosidase deficiency with glycogen accumulation in lysosomes, responds to enzyme replacement with alglucosidase alfa. Fabry disease, caused by α-galactosidase A deficiency, is treated with agalsidase alfa or beta.

Summary

Enzymes are biological catalysts that accelerate reactions by lowering activation energy, and understanding their kinetics is fundamental to biochemistry and pharmacology. Michaelis-Menten kinetics describes the relationship between substrate concentration and reaction velocity, characterized by two key parameters: Km (reflecting substrate affinity) and Vmax (reflecting maximal catalytic capacity). The Lineweaver-Burk plot linearizes this relationship, facilitating parameter determination and inhibition analysis. Reversible inhibition comes in four types—competitive, non-competitive, uncompetitive, and mixed—each with characteristic effects on kinetic parameters that can be visualized on Lineweaver-Burk plots. Allosteric enzymes display sigmoidal kinetics and switch-like regulation through conformational equilibria between T and R states. Covalent modifications, particularly phosphorylation, provide rapid reversible regulation through the opposing actions of kinases and phosphatases. Zymogens offer irreversible activation control for enzymes like digestive proteases and clotting factors. These principles directly inform drug design and enable enzyme replacement therapies for inherited metabolic diseases.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown